Introducing AlluVI: A Novel Dual GIP and GLP-1 RA

AlluVI embodies a substantial advance in diabetic management. This distinct therapeutic compound functions as a combined focusing both Glucose-dependent Insulinotropic Polypeptide (the GIP hormone) and Glucagon-like Peptide-1 Receptor activator (GLP-1 RA). The hope with AlluVI exists in its ability to boost glycemic regulation and perhaps offer add

read more